Vaccine testing at Porton Down to be expanded under plans to ‘future-proof’ UK against Covid

Government hopes £30m investment will lead to jabs capable of neutralising new and emerging variants

<p>Testing at the Porton Down labs in Wiltshire will be ramped up</p>

Testing at the Porton Down labs in Wiltshire will be ramped up

The government is investing almost £30m in expanding laboratories that will assess the effectiveness of vaccines against emerging coronavirus variants.

Under plans to “future-proof” the UK against more infectious or immune-escaping forms of the virus, testing is to be increased at the Porton Down labs in Wiltshire, enabling scientists elsewhere to fast-track the development of new and existing vaccines.

The top-secret facilities measure the levels of antibodies within vaccinated or naturally infected people’s blood and test whether these proteins can neutralise the different variants that have been detected to date.

The extra funding will increase the site’s capacity from 700 tests being sampled a week to 3,000, according to the government.

It’s hoped the extra research will help Porton Down scientists to support the rapid development of vaccines designed to combat the different mutations that have been emerging in Sars-CoV-2 – the virus responsible for Covid-19.

Experts say mutations could spark a new, more infectious wave of coronavirus spreading in the UK. Jenny Harries, chief executive at the UK Health Security Agency, said: “A new variant that can escape the current vaccines is the greatest risk of a third wave. This new investment will help us stay one step ahead of the virus by doubling our capacity to test vaccine effectiveness against emerging variants.

“While we expect the existing vaccines to offer protection against new variants, particularly preventing serious illness and death, it is important that we continue to monitor the picture as it develops.”

Early evidence suggests that the current vaccines are effective against the variants that were originally detected in Kent and South Africa.

The full impact of the other known variants, such as those found in India and Manaus, has yet to be ascertained, with laboratory testing ongoing.

The new funding, which brings recent expenditure on Porton Down to £49m, is part of a £6bn budget put aside for the development, manufacturing and procurement of Covid-19 vaccines as the UK steps out of the acute phase of its epidemic.

“Our vaccination programme has so far saved thousands of lives, but it’s vital we put in place robust support for the programme for the future,” said vaccines minster Nadhim Zahawi.

Manufacturers such as AstraZeneca and Pfizer are also exploring the possibility of updating their vaccines to target the concerning mutations seen in the new coronavirus variants.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in